(Total Views: 802)
Posted On: 06/20/2020 3:33:35 PM
Post# of 72440
I agree the only tenable strategy for the shorts is to cover as soon as possible and recover when they have pushed the price up to unreasonable levels. IPIX should be in a favorable new cycle for few months. If the shorters discover this epiphany too late they will not be able to dig themselves out of a large hole. The Fudsters postings have already increased the possible buy out number from 1 to 3 billion a few weeks ago to 8-10billion the last couple of days
The RBL data is in and it is conclusive...Brilacidin is effective in a battery of in vitro tests for Covid 19 in human respiratory and kidney cells.
The RBL researchers were so impressed with the results; they are both going to submit their results for peer review publication which will be expedited.
Last week the RBLs in collaboration with IPIX submitted a federal grant application for not only Covid19, but also other coronaviruses , MERS and Sars, as well as, other RNA viruses which cause viral encephalitis and other disorders.
The company is preparing for human trials by manufacturing IV Brilacidin.
The question one should askis ; what is the competition?
How many drugs have the RBL recommended for clinical trials?
None as far as far I can tell.
How many drugs have been referred by independent labs for Covid 19 clinical trials?
Hydroxychloroquine has been shown to be ineffective in several trials
Ivermectim, an antiparasitic agent, has shown mixed results,but questions remain about the dosage and the quality of the studies.
https://www.isglobal.org/en/healthisglobal/-/.../2877257/0
What about drugs sponsored in clinical trials by their companies.
The best known example is Gilead's Remdesivir. Remdesivir has shown to be beneficial when patients first developed pulmonary symptoms but did not produce a statistically significant improvement in more severely ill patients.
https://www.usnews.com/news/health-news/artic...tudy-finds
Other antiviral drugs studied such as lopinavir/ritonavir, Umifenovir have been ineffective.
Antiinflammatorty agents: Decamethasone was recently reported to lower the death rate by 30% in severly ill patients, but previous studies if corticosteroids suggested no benefit or even a higher death rate.
https://www.economist.com/britain/2020/06/20/...-19-deaths
Tocilizumab was recently shown to not be of benefit in pulmonary Covid 19 after several early reports of success. Sarilumab{Kezara}
has had disappointing studies recently.
https://www.fiercepharma.com/pharma/roche-s-a...-pneumonia
Many other drugs are at early stages of invesigation.
https://emedicine.medscape.com/article/2500114-treatment#d14
In summary Brilacidin's test results are outstanding and the federal grant and clinical trial should be announced soon.
The competition at this point is relatively weak and the bar for success is very low. The RBLs are a division of Dr Fauci's NIAID; it is safe to assume leaders in the NIH,HHS as well as the Trump administration are aware of Brilacidin's progress.
The world is desperate for a treatment for Covid 19 and no other drug offers the potential of Brilacidin as a safe virucidal and a quick acting drug with multiple mechanisms of action. It possesses antibiotic and immunomodulary effects which seem custom made for Covid 19 and perhaps many other viral diseases. It is expected to have the ability to avoid viral drug resistance.
My guess is we will receive the grant announcement next week. The announcement of clinical trials will follow.
GLTA Farrell
"Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of
for other clinical indications, providing an established safety and efficacy database on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Ongoing laboratory testing conducted at a U.S. Regional Biocontainment Laboratory (RBL), and at a Public Health Research Institute (PHRI), supports Brilacidin’s antiviral ability to safely inhibit SARS-CoV-2 in both human and animal cell lines. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Additional pre-clinical and clinical data support Brilacidin’s potential to inhibit IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. These data collectively support Brilacidin as a unique 3 in 1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—anti-COVID-19 therapeutic candidate."
The RBL data is in and it is conclusive...Brilacidin is effective in a battery of in vitro tests for Covid 19 in human respiratory and kidney cells.
The RBL researchers were so impressed with the results; they are both going to submit their results for peer review publication which will be expedited.
Last week the RBLs in collaboration with IPIX submitted a federal grant application for not only Covid19, but also other coronaviruses , MERS and Sars, as well as, other RNA viruses which cause viral encephalitis and other disorders.
The company is preparing for human trials by manufacturing IV Brilacidin.
The question one should askis ; what is the competition?
How many drugs have the RBL recommended for clinical trials?
None as far as far I can tell.
How many drugs have been referred by independent labs for Covid 19 clinical trials?
Hydroxychloroquine has been shown to be ineffective in several trials
Ivermectim, an antiparasitic agent, has shown mixed results,but questions remain about the dosage and the quality of the studies.
https://www.isglobal.org/en/healthisglobal/-/.../2877257/0
What about drugs sponsored in clinical trials by their companies.
The best known example is Gilead's Remdesivir. Remdesivir has shown to be beneficial when patients first developed pulmonary symptoms but did not produce a statistically significant improvement in more severely ill patients.
https://www.usnews.com/news/health-news/artic...tudy-finds
Other antiviral drugs studied such as lopinavir/ritonavir, Umifenovir have been ineffective.
Antiinflammatorty agents: Decamethasone was recently reported to lower the death rate by 30% in severly ill patients, but previous studies if corticosteroids suggested no benefit or even a higher death rate.
https://www.economist.com/britain/2020/06/20/...-19-deaths
Tocilizumab was recently shown to not be of benefit in pulmonary Covid 19 after several early reports of success. Sarilumab{Kezara}
has had disappointing studies recently.
https://www.fiercepharma.com/pharma/roche-s-a...-pneumonia
Many other drugs are at early stages of invesigation.
https://emedicine.medscape.com/article/2500114-treatment#d14
In summary Brilacidin's test results are outstanding and the federal grant and clinical trial should be announced soon.
The competition at this point is relatively weak and the bar for success is very low. The RBLs are a division of Dr Fauci's NIAID; it is safe to assume leaders in the NIH,HHS as well as the Trump administration are aware of Brilacidin's progress.
The world is desperate for a treatment for Covid 19 and no other drug offers the potential of Brilacidin as a safe virucidal and a quick acting drug with multiple mechanisms of action. It possesses antibiotic and immunomodulary effects which seem custom made for Covid 19 and perhaps many other viral diseases. It is expected to have the ability to avoid viral drug resistance.
My guess is we will receive the grant announcement next week. The announcement of clinical trials will follow.
GLTA Farrell
"Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of
for other clinical indications, providing an established safety and efficacy database on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Ongoing laboratory testing conducted at a U.S. Regional Biocontainment Laboratory (RBL), and at a Public Health Research Institute (PHRI), supports Brilacidin’s antiviral ability to safely inhibit SARS-CoV-2 in both human and animal cell lines. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Additional pre-clinical and clinical data support Brilacidin’s potential to inhibit IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. These data collectively support Brilacidin as a unique 3 in 1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—anti-COVID-19 therapeutic candidate." 
(8)
(0)Scroll down for more posts ▼
